Bit Digital Inc vs Cronos Group Inc — how do they compare? Bit Digital Inc trades at $1.43 (market cap $471.05M), while Cronos Group Inc trades at $3.07 (market cap $1.14B). The key difference: Cronos Group Inc is far larger — about 2.4× Bit Digital Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BTBT | CRON | |
|---|---|---|
Market Cap | $471.05M | $1.14B |
Sector | Technology | Health |
52-Week High | $4.22 | $3.27 |
52-Week Low | $1.23 | $2.30 |
Enterprise Value | $760.36M | $341.13M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Trailing returns across standard periods
Latest headlines on both assets
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →